Olodaterol/tiotropium bromide - Boehringer Ingelheim
Alternative Names: BI-1744-CL/tiotropium bromide; Spiolto Respimat; Stiolto; STIOLTO RESPIMAT; Tiotropium bromide/BI-1744-CL; Tiotropium bromide/olodaterol; Vahelva RespimatLatest Information Update: 21 Nov 2021
At a glance
- Originator Boehringer Ingelheim
- Class Amines; Benzoxazines; Bronchodilators; Epoxy compounds; Esters; Ketones; Small molecules; Thiophenes; Tropanes
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 08 Sep 2021 Launched for Chronic obstructive pulmonary disease in France, Greece, Hungary, Portugal, Belgium, New Zealand, Israel, Germany, Sweden, Poland, Chile, Russia, Philippines, Netherlands, Czech Republic, Indonesia, Hong Kong, Argentina, Switzerland, Turkey, Mexico, Singapore, Ukraine (Inhalation) before September 2021
- 08 Sep 2021 No development reported - Phase-III for Chronic obstructive pulmonary disease in Guatemala, Colombia, South Africa, Malaysia, Serbia, Taiwan, Brazil, India, Peru, Vietnam, Thailand (Inhalation)
- 17 May 2019 Updated efficacy data from the phase III DYNAGITO trial in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)